Synthesis and Antimicrobial Activity of Adamantyl Substituted Pyridoxine Derivatives
-
Published:2019-11-08
Issue:12
Volume:16
Page:1360-1369
-
ISSN:1570-1808
-
Container-title:Letters in Drug Design & Discovery
-
language:en
-
Short-container-title:LDDD
Author:
Khaziev Rail1, Shtyrlin Nikita1ORCID, Pavelyev Roman1, Nigmatullin Raushan1, Gabbasova Raylya1, Grishaev Denis1, Shtro Anna2, Galochkina Anastasia2, Nikolaeva Yulia2, Vinogradova Tatiana3, Manicheva Olga3, Dogonadze Marine3, Gnezdilov Oleg4, Sokolovich Evgenii3, Yablonskiy Petr3, Balakin Konstantin1, Shtyrlin Yurii1ORCID
Affiliation:
1. Scientific and Educational Center of Pharmaceutics, Kazan (Volga Region) Federal University, Kazan, Russian Federation 2. Laboratory for Chemotherapy of Viral Infections, Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation 3. Saint Petersburg Research Institute of Phthisiopulmonology, Saint Petersburg, Russian Federation 4. Zavoisky Physical- Technical Institute, FRC Kazan Scientific Center, RAS, Kazan, Russia; 5Saint Petersburg State University, Saint Petersburg, Russian Federation
Abstract
Background:
Adamantane derivatives possess multiple pharmacological activities such
as antiviral, anticancer, antimycobacterial, antidiabetic, antiparkinsonian and others. The interest of
medicinal chemists in adamantane compounds is due to their unique spatial structure, high lipophilicity,
and carbon cage rigidity. As a result, these molecules can easily penetrate biological lipid
membranes and often have unique target-specific activity profile. Another pharmacophore studied in
this work is pyridoxine (vitamin B6). Pyridoxine plays highly important roles in living cells as a key
cofactor of many enzymes. On the other hand, its molecular scaffold is a valuable structural platform
which has led to the development of several launched drugs (Pyritinol, Pirisudanol, Cycletanine,
Mangafodipir) and a wide number of preclinical and clinical drug candidates.
Objective:
The objective of this study is a synthesis of pyridoxine-adamantane and pyridoxinecyclooctane
dipharmacophore molecules. The underlying idea was to assess the antibacterial and
antiviral potential of such dipharmacophores, based on multiple examples of promising antiinfective
agents which have in their structures adamantane and pyridoxine moieties. Another specific reason
was to explore the ability of pyridoxine pharmacophore to suppress the potential of microbial pathogens
to develop resistance to drug molecules.
Methods:
In this study, a series of pyridoxine-adamantane and pyridoxine-cyclooctane dipharmacophore
molecules were synthesized based on reactions of three different cycloalkyl amines with the
corresponding electrophilic derivatives of pyridoxine aldehydes, chlorides and acetates. All synthesized
compounds have been tested for their in vitro activity against M. tuberculosis H37Rv strain and
H3N2 (A/Aichi/2/68) influenza virus.
Results:
Series of pyridoxine-adamantane and pyridoxine-cyclooctane dipharmacophore molecules
were synthesized based on reactions of three different cycloalkylamines with the corresponding
electrophilic derivatives of pyridoxine aldehydes, chlorides and acetates. Reaction of cycloalkylamines
with pyridoxine derivatives, in which meta-hydroxyl and ortho-hydroxymethyl groups are
protected by acetyl groups, represents a useful alternative to reductive amination of aldehydes and
nucleophilic substitution of alkyl halides. According to a tentative mechanism, it proceeds via paraand
ortho-pyridinone methides which readily react with nucleophiles. None of the synthesized dipharmacophore
compounds showed activity against M. tuberculosis H37Rv strain. At the same time,
three compounds demonstrated some antiviral activity against H3N2 (A/Aichi/2/68) influenza virus
(EC50 52-88 µg/mL) that was comparable to the activity of Amantadine, though lower than the activity
of Rimantadine. The results of this work can be useful in the design of physiologically active
derivatives of pyridoxine and adamantane.
Conclusion:
The results of this work can be useful in the design of physiologically active derivatives
of pyridoxine and adamantane.
Funder
Russian Science Foundation
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference23 articles.
1. Wanka L.; Iqbal K.; Schreiner P.R.; The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev 2013,113(5),3516-3604 2. Liu J.; Obando D.; Liao V.; Lifa T.; Codd R.; The many faces of the adamantyl group in drug design. Eur J Med Chem 2011,46(6),1949-1963 3. Lamoureux G.; Artavia G.; Use of the adamantane structure in medicinal chemistry. Curr Med Chem 2010,17(26),2967-2978 4. Sacksteder K.A.; Protopopova M.; Barry C.E.; Andries K.; Nacy C.A.; Discovery and development of SQ109: A new antitubercular drug with a novel mechanism of action. Future Microbiol 2012,7(7),823-837 5. Beena; Kumar, D.; Kumbukgolla, W.; Jayaweera, S.; Bailey, M.; Alling, T.; Ollinger, J.; Parish, T.; Rawat, D.S. Antibacterial activity of adamantyl substituted cyclohexane diamine derivatives against methicillin resistant Staphylococcus aureus and Mycobacterium tuberculosis. RSC Advances 2014,4(23),11962-11966
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|